Related Experiment Video
Updated: Jan 16, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer
Neele Wüstmann1, Julissa Reimann1, Julia Vieler1
1Department of Urology, University Hospital Muenster, Germany.
Abstract:
This study aimed to comprehensively analyze AR-V specific target gene expression using a physiological system that simulates the actual situation of AR-FL and AR-V co-appearance in prostate cancer patients. Clinically described AR splice variants AR-V3, AR-V7 and AR-V9 were transfected along with AR-FL in AR-negative prostate cancer PC-3 cells. RNA sequencing analysis showed only slight differences in differentially expressed genes between AR-FL and AR-V co-expressing cells compared to solely AR-FL expressing cells. Immunofluorescence analysis and luciferase assays revealed hormonal dependency of AR-FL, constitutive activity of AR-V7, and ambivalent activity of AR-V9, while AR-V3 showed no activity. Analysis of a set of published target genes showed steady upregulation of EDN2 and FKBP5. Yet, clinical analysis revealed no significant differences in overall survival data in prostate cancer patients. The study challenges the existence of an AR-V specific transcriptome responsible for treatment resistance and tumor progression and highlights the need for further investigation into the molecular mechanism by which AR-V proteins route resistance to ARTA treatment.
Insights
This study investigated androgen receptor splice variants (AR-V) in prostate cancer, finding no distinct AR-V transcriptome driving treatment resistance. Further research is needed to understand AR-V
Area of Science:
- Molecular Oncology
- Prostate Cancer Research
- Gene Expression Analysis
Background:
- Androgen receptor (AR) signaling is crucial in prostate cancer progression.
- AR splice variants (AR-Vs) are implicated in resistance to androgen-deprivation therapies (ARTAs).
- The specific role of AR-Vs in treatment resistance and tumor progression remains incompletely understood.
Purpose of the Study:
- To comprehensively analyze AR-V specific target gene expression in a model simulating co-occurrence of full-length AR (AR-FL) and AR-Vs.
- To investigate the functional activity of clinically relevant AR-Vs (AR-V3, AR-V7, AR-V9) in prostate cancer cells.
- To challenge the hypothesis of an AR-V specific transcriptome driving treatment resistance.
Main Methods:
- Transfection of AR-FL and AR-V variants (AR-V3, AR-V7, AR-V9) into AR-negative PC-3 prostate cancer cells.
- RNA sequencing to analyze differential gene expression.
- Immunofluorescence and luciferase assays to determine protein activity.
- Analysis of published target genes and clinical survival data.
Main Results:
- RNA sequencing revealed minimal differences in gene expression between AR-FL and co-expressing AR-V cells.
- AR-V7 exhibited constitutive activity, AR-V9 showed ambivalent activity, AR-V3 was inactive, and AR-FL was hormone-dependent.
- Upregulation of EDN2 and FKBP5 was observed, but clinical analysis showed no significant impact of AR-Vs on patient survival.
Conclusions:
- The study challenges the existence of a distinct AR-V specific transcriptome driving treatment resistance and tumor progression.
- The molecular mechanisms by which AR-V proteins contribute to resistance to ARTA treatment require further investigation.
- Clinical outcomes did not correlate with the presence of AR-Vs in this study cohort.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
What is Gene Expression?

